Khaled Shalaby

1.3k total citations · 1 hit paper
40 papers, 1.0k citations indexed

About

Khaled Shalaby is a scholar working on Pharmaceutical Science, Molecular Biology and Food Science. According to data from OpenAlex, Khaled Shalaby has authored 40 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pharmaceutical Science, 7 papers in Molecular Biology and 7 papers in Food Science. Recurrent topics in Khaled Shalaby's work include Advancements in Transdermal Drug Delivery (18 papers), Advanced Drug Delivery Systems (14 papers) and Drug Solubulity and Delivery Systems (11 papers). Khaled Shalaby is often cited by papers focused on Advancements in Transdermal Drug Delivery (18 papers), Advanced Drug Delivery Systems (14 papers) and Drug Solubulity and Delivery Systems (11 papers). Khaled Shalaby collaborates with scholars based in Saudi Arabia, Egypt and United Kingdom. Khaled Shalaby's co-authors include Mohammed Elmowafy, Mohammed H. Elkomy, Mohamed A. Abdelgawad, Ayman Salama, Ameeduzzafar Zafar, Omar Awad Alsaidan, Nabil K. Alruwaili, Ehab M. Mostafa, Hazim M. Ali and Hesham A. M. Gomaa and has published in prestigious journals such as Molecules, International Journal of Pharmaceutics and RSC Advances.

In The Last Decade

Khaled Shalaby

40 papers receiving 993 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Polymeric Nanoparticles for Delivery of Natural Bioactive Agents: Recent Advances and Challenges

2023 158 citations Mohammed Elmowafy, Khaled Shalaby et al. Polymers profile →

Peers

Countries citing papers authored by Khaled Shalaby

Since Specialization

Citations

This map shows the geographic impact of Khaled Shalaby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Khaled Shalaby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Khaled Shalaby more than expected).

Fields of papers citing papers by Khaled Shalaby

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Khaled Shalaby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Khaled Shalaby. The network helps show where Khaled Shalaby may publish in the future.

Co-authorship network of co-authors of Khaled Shalaby

This figure shows the co-authorship network connecting the top 25 collaborators of Khaled Shalaby. A scholar is included among the top collaborators of Khaled Shalaby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Khaled Shalaby. Khaled Shalaby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	In Vitro and In Vivo Appraisal of Glycerylmonostearate/chitosan Hybrid Nanocapsules As Peroral Delivery System of Simvastatin 2025 ·AAPS PharmSciTech ·Mohammed Elmowafy, Khaled Shalaby, Nabil K. Alruwaili, Omar Awad Alsaidan, Mohammed H. Elkomy, (unknown), Ehab M. Mostafa, Ayman Salama, (unknown), Mohamed F. Ibrahim, (unknown)	1
2	Intranasal Nanotransferosomal Gel for Quercetin Brain Targeting: II. Antidepressant Effect in an Experimental Animal Model 2023 ·Pharmaceutics ·Mohammed H. Elkomy, Fatma I. Abo El‐Ela, Randa Mohammed Zaki, Omar Awad Alsaidan, Mohammed Elmowafy, Ameeduzzafar Zafar, Khaled Shalaby, Mohamed A. Abdelgawad, Hany A. Omar, Rania Salama, Hussein M. Eid	14
3	Phenylpyrazolone-1,2,3-triazole Hybrids as Potent Antiviral Agents with Promising SARS-CoV-2 Main Protease Inhibition Potential 2023 ·Pharmaceuticals ·Arafa Musa, Hamada S. Abulkhair, Ateyatallah Aljuhani, Nadjet Rezki, Mohamed A. Abdelgawad, Khaled Shalaby, Ahmed H. El‐Ghorab, Mohamed Reda Aouad	39
4	Polymeric Nanoparticles for Delivery of Natural Bioactive Agents: Recent Advances and Challenges breakdown → 2023 ·Polymers ·Mohammed Elmowafy, Khaled Shalaby, Mohammed H. Elkomy, Omar Awad Alsaidan, Hesham A. M. Gomaa, Mohamed A. Abdelgawad, Ehab M. Mostafa	158
5	Intranasal Nanotransferosomal Gel for Quercetin Brain Targeting: I. Optimization, Characterization, Brain Localization, and Cytotoxic Studies 2023 ·Pharmaceutics ·Mohammed H. Elkomy, Randa Mohammed Zaki, Omar Awad Alsaidan, Mohammed Elmowafy, Ameeduzzafar Zafar, Khaled Shalaby, Mohamed A. Abdelgawad, Fatma I. Abo El‐Ela, Mostafa E. Rateb, Ibrahim A. Naguib, Hussein M. Eid	24
6	Exploring the potential of quercetin/aspirin-loaded chitosan nanoparticles coated with Eudragit L100 in the treatment of induced-colorectal cancer in rats 2023 ·Drug Delivery and Translational Research ·Mohammed Elmowafy, Khaled Shalaby, Mohammed H. Elkomy, Omar Awad Alsaidan, Hesham A. M. Gomaa, Omnia M. Hendawy, Mohamed A. Abdelgawad, Hazim M. Ali, (unknown), Khalid M. El‐Say	17
7	The anticancer and EGFR-TK/CDK-9 dual inhibitory potentials of new synthetic pyranopyrazole and pyrazolone derivatives: X-ray crystallography, in vitro , and in silico mechanistic investigations 2023 ·Journal of Biomolecular Structure and Dynamics ·Arafa Musa, Saleh Ihmaid, David L. Hughes, Musa A. Said, Hamada S. Abulkhair, Ahmed H. El‐Ghorab, Mohamed A. Abdelgawad, Khaled Shalaby, Mohamed E. Shaker, Khalid Saad Alharbi, Nasser Hadal Alotaibi, Deborah L. Kays, Laurence J. Taylor, Della Grace Thomas Parambi, Sami I. Alzarea, Ahmed A. Al‐Karmalawy, Hany E. A. Ahmed, Ahmed M. El‐Agrody	33
8	Repurposing celecoxib for colorectal cancer targeting via pH-triggered ultra-elastic nanovesicles: Pronounced efficacy through up-regulation of Wnt/β-catenin pathway in DMH-induced tumorigenesis 2023 ·International Journal of Pharmaceutics X ·Shahira F. El Menshawe, Khaled Shalaby, Mohammed H. Elkomy, Heba M. Aboud, (unknown), (unknown), (unknown), (unknown), Amani M. El Sisi	5
9	In Vitro Anti-Proliferative, and Kinase Inhibitory Activity of Phenanthroindolizidine Alkaloids Isolated from Tylophora indica 2022 ·Plants ·Ehab M. Mostafa, Hamdoon A. Mohammed, Arafa Musa, Mohamed A. Abdelgawad, Mohammad M. Al‐Sanea, Suliman A. Almahmoud, Mohammed M. Ghoneim, Hesham A. M. Gomaa, (unknown), Khaled Shalaby, Samy Selim, Riaz A. Khan	3
10	Development and assessment of phospholipid-based luteolin-loaded lipid nanocapsules for skin delivery 2022 ·International Journal of Pharmaceutics ·Mohammed Elmowafy, Khaled Shalaby, Mohammed H. Elkomy, Omar Awad Alsaidan, Hesham A. M. Gomaa, Mohamed A. Abdelgawad, Diaa Massoud, Ayman Salama, Khalid M. El‐Say	16
11	A validated LC–MS/MS method for analysis of Cabergoline in human plasma with its implementation in a bioequivalent study: investigation of method greenness 2022 ·BMC Chemistry ·Khaled Shalaby, Saleh Alghamdi, Mohammed Gamal, (unknown), (unknown)	1
12	EthoLeciplex: a new tool for effective cutaneous delivery of minoxidil 2022 ·Drug Development and Industrial Pharmacy ·Mohammed Elmowafy, Khaled Shalaby, Nabil K. Alruwaili, Mohammed H. Elkomy, Ameeduzzafar Zafar, Ghareb M. Soliman, Ayman Salama, (unknown)	6
13	Impact of highly phospholipid-containing lipid nanocarriers on oral bioavailability and pharmacodynamics performance of genistein 2022 ·Pharmaceutical Development and Technology ·Mohammed Elmowafy, Khaled Shalaby, Mohammed H. Elkomy, Nabil K. Alruwaili, Ehab M. Mostafa, Muhammad Afzal, Khalid Saad Alharbi, (unknown), Hazim M. Ali, Ayman Salama, (unknown)	10
14	Effect of Olive Oil Acidity on Skin Delivery of Diclofenac: In Vitro Evaluation and Ex Vivo Skin Permeability Studies 2022 ·Journal of Biomedical Nanotechnology ·Khaled Shalaby	4
15	Potential of Natural Bioactive Compounds in Management of Diabetes: Review of Preclinical and Clinical Evidence 2021 ·Current Pharmacology Reports ·Ameeduzzafar Zafar, Nabil K. Alruwaili, Dibya Sundar Panda, Syed Sarim Imam, Khalid Saad Alharbi, Muhammad Afzal, Khaled Shalaby, Imran Kazmi, Sultan Alshehri	9
16	Assessment of Knowledge of Diabetic Patients about Glycemic Abnormalities and Medicine Storage in Makkah during Hajj Pilgrimage 2020 ·Indian Journal of Pharmaceutical Education and Research ·(unknown), Aejaz Abdullatif Khan, S. M. Shakeel Iqubal, (unknown), Muazzam Sheriff Maqbul, Mohammed Gamal, Mohammad M. Al‐Sanea, Mohammed Elmowafy, Khaled Shalaby, Dibya Sundar Panda, Saleh Alghamdi	2
17	Impact of nanostructured lipid carriers on dapsone delivery to the skin: in vitro and in vivo studies 2019 ·International Journal of Pharmaceutics ·Mohammed Elmowafy, Khaled Shalaby, Hazim M. Ali, Nabil K. Alruwaili, Ayman Salama, Mohamed F. Ibrahim, Mohamed A. Akl, Tarek A. Ahmed	44
18	Multifunctional carbamazepine loaded nanostructured lipid carrier (NLC) formulation 2018 ·International Journal of Pharmaceutics ·Mohammed Elmowafy, Khaled Shalaby, Mohamed M. Badran, Hazim M. Ali, Mohamed S. Abdel‐Bakky, Hussein Ibrahim	59
19	Human Skin Penetration and Distribution via Different Vesicular Systems 2014 ·British Journal of Pharmaceutical Research ·Khaled Shalaby, Ming Chen, Mohammed Elmowafy, Alfred Fahr	1
20	Influence of the Flexible Liposomes on the Skin Deposition of a Hydrophilic Model Drug, Carboxyfluorescein: Dependency on Their Composition 2012 ·The Scientific World JOURNAL ·Mohamed M. Badran, Khaled Shalaby, Abdullah H. Alomrani	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact